Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | BCL9 | O00512 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13397963 | 0.85 | CYP1A2 (0.51) | CYP1A2CYP2D6GAAMGLLDPP4 | |
| SCHEMBL13397965 | 0.85 | CYP1A2 (0.51) | CYP1A2CYP2D6GAAMGLLDPP4 | |
| SCHEMBL11199297 | 0.84 | F2 (0.47) | DPP4DPP7DPP8DPP9KMT2A | |
| SCHEMBL11201890 | 0.82 | GAA (0.40) | GAADPP4DPP7FAPDPP8 | |
| SCHEMBL2105035 | 0.82 | CYP1A2 (0.57) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL11199531 | 0.81 | DPP4 (0.41) | MGLLDPP4DPP7FAPDPP8 | |
| SCHEMBL11192858 | 0.81 | DPP4 (0.43) | MGLLDPP4DPP7FAPDPP8 | |
| SCHEMBL11193214 | 0.81 | CHRNA7 (0.52) | CYP1A2DPP4DPP7FAPDPP8 | |
| SCHEMBL11197237 | 0.81 | CHRNA7 (0.52) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL11192920 | 0.81 | DPP4 (0.41) | GAADPP4DPP7FAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027041-B1 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | AMPLIMED INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030129222-A1 | Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer | VALLEY VENTURES III, L.P. | 2003-07-10 | — | — | US | disclosed |
| WO-2002041871-A9 | COMPOSITION COMPRISING AN IMEXON OR DERIVATIVES THEREOF AND LIPIDS | UNIV TEXAS (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002041871-A2 | COMPOSITION COMPRISING AN IMEXON OR DERIVATIVES THEREOF AND LIPIDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-05-30 | — | — | WO | disclosed |
| US-6297230-B1 | N-CARBAMOYL-SUBSTITUTED | AMPLIMED, INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1027041-A4 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | UNIV ARIZONA (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-1027041-A1 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | THE ARIZONA BOARD OF REGENTS, ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999000120-A1 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | ARIZONA BOARD OF REGENTS, UNIVERSITY OF ARIZONA (US) | 1999-01-07 | — | — | WO | disclosed |
| US-4376731-A | 2-NITRILES THEREOF | BOEHRINGER MANNHEIM GMBH (DE) | 1983-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129222-A1 | Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer | ABHD16A, PNLIP, LIPA | CYP1A2 2208/4885CYP2D6 284/4885GAA 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.